EUVIMEDOpdag EUVIMED
Crossref

Relaxin‐2 promotes osteoblastic differentiation mediated by epidermal growth factor and epidermal growth factor receptor signaling

Lankai Yi, Ning Han, Zhong Li, Housen Jiang, Zhenhao Cao iD

Biotechnology and Applied Biochemistry · 2025

DOI: 10.1002/bab.2661 ↗

At a glance

Journal article in Biotechnology and Applied Biochemistry, 2025. Written by Lankai Yi and 4 co-authors. Institution: Department of Hand, Foot, and Orthopedics Surgery, Weifang People's Hospital, Weifang, Shandong Province, China. Major MEDLINE topics: Osteoblasts, ErbB Receptors, Cell Differentiation, Signal Transduction. Cited 4 times so far (Crossref); 55 references. Funded by: Weifang Health Commission Research Project.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Loss of osteogenic differentiation potential of osteoblasts has been associated with the pathogenesis of osteoporosis. Thus, stimulation of osteoblastic differentiation is a therapeutic strategy for osteoporosis. Relaxin‐2 is a peptide hormone with potent biological functions. However, the effects of Relaxin‐2 in osteoblastic differentiation and osteoporosis have not been reported before. Here, we report a novel physiological role of Relaxin‐2 in promoting osteoblastic differentiation and mineralization of MC3T3‐E1 cells. Our results indicate that exposure to Relaxin‐2 upregulated the expression, and elevated the activity of alkaline phosphatase (ALP) when MC3T3‐E1 cells were cultured in osteogenic differentiation medium (OM). Additionally, Relaxin‐2 upregulated the mRNA levels of osteocalcin ( ocn ), osteopontin ( opn ), and collagen type I alpha 1 ( Col1a1 ). The alizarin red S staining assay revealed that Relaxin‐2 promoted the mineralization of MC3T3‐E1 cells. We also found that Relaxin‐2 increased the expression of Runx‐2 as well as the epidermal growth factor ( EGF ) and epidermal growth factor receptor ( EGFR ). Importantly, silencing of EGF abolished the effects of Relaxin‐2 in osteoblastic differentiation and related gene expression. These findings suggest that Relaxin‐2 stimulates osteogenic differentiation through activating EGF/EGFR signaling.

Subjects

MeSH terms (MEDLINE)

OsteoblastsErbB ReceptorsCell DifferentiationSignal TransductionRelaxinEpidermal Growth FactorMiceAnimalsOsteogenesisCell Line

Author keywords

EGFRunx‐2osteoblastic differentiationosteoporosis

Substances

ErbB ReceptorsRelaxinEpidermal Growth FactorEGFR protein, mouse

Authors and institutions

  • Department of Hand, Foot, and Orthopedics Surgery, Weifang People's Hospital, Weifang, Shandong Province, China.

ORCID profiles: Zhenhao Cao

Funding

  • Weifang Health Commission Research Project

Cite

APA

Yi, L., Han, N., Li, Z., Jiang, H., & Cao, Z. (2025). Relaxin‐2 promotes osteoblastic differentiation mediated by epidermal growth factor and epidermal growth factor receptor signaling. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.2661

Vancouver

Yi L, Han N, Li Z, Jiang H, Cao Z. Relaxin‐2 promotes osteoblastic differentiation mediated by epidermal growth factor and epidermal growth factor receptor signaling. Biotechnology and Applied Biochemistry. 2025. doi:10.1002/bab.2661

BibTeX
@article{Yi2025,
  author = {Yi, Lankai and Han, Ning and Li, Zhong and Jiang, Housen and Cao, Zhenhao},
  title = {Relaxin‐2 promotes osteoblastic differentiation mediated by epidermal growth factor and epidermal growth factor receptor signaling},
  journal = {Biotechnology and Applied Biochemistry},
  year = {2025},
  doi = {10.1002/bab.2661}
}
Start for free →